Vistagen Therapeutics (VTGN) Receivables - Net (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Receivables - Net of $56000.0 for Q1 2026, down 24.32% sequentially from $74000.0 in Q4 2025, and down 56.92% YoY from $130000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Receivables - Net (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Receivables - Net for 10 years, with the latest figure at $56000.0 in Q1 2026.
- Quarterly Receivables - Net fell 56.92% year-over-year to $56000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56000.0 (down 56.92% YoY) and the FY2026 annual result came in at $56000.0, down 56.92% from the prior year.
- Receivables - Net retreated to $56000.0 in Q1 2026 per VTGN's latest filing, from $74000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $285000.0 in Q1 2023 and troughed at $56000.0 in Q1 2026.
- A 5-year average of $163007.7 and a median of $167000.0 in 2024 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2026: Receivables - Net jumped 392.61% in 2022, then tumbled 56.92% in 2026.
- Over 5 years, Receivables - Net stood at $200000.0 in 2022, then advanced by 11.6% to $223200.0 in 2023, then slumped by 33.24% to $149000.0 in 2024, then plunged by 50.34% to $74000.0 in 2025, then dropped by 24.32% to $56000.0 in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $56000.0, $74000.0, and $92000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Vistagen Therapeutics | 10.50 Mn | 10.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Sep 30, 2024 | 167,000.00 |
| Sep 30, 2024 | 167,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Dec 31, 2023 | 223,200.00 |
| Dec 31, 2023 | 223,200.00 |